加载中
NASDAQHealthcareBiotechnology
最新数据
US$7.145
−US$0.155 · -2.12%
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
常规交易时段
US$7.145
−US$0.155 · -2.12%
盘中时间采用ET。市场数据可能有所延迟。
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
日内区间
当前US$7.145
52周区间
当前US$7.145
盘中时间采用ET。市场数据可能有所延迟。
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
日内区间
当前US$7.145
52周区间
当前US$7.145
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1310.7万 USD | 1009.4万 USD | 776.8万 USD | — | — |
| 销货成本 | 856.5万 USD | 776.5万 USD | 474.1万 USD | — | — |
| 毛利 | 454.2万 USD | 232.9万 USD | 302.7万 USD | — | — |
| 研究与开发 | 4448.6万 USD | 4044.8万 USD | 8665.5万 USD | 8187.6万 USD | 6883.8万 USD |
| 销售、一般及管理费用 | 8575.9万 USD | 4010.1万 USD | 3475.2万 USD | 3021.5万 USD | 2347.4万 USD |
| 营业费用 | 1.3亿 USD | 1.39亿 USD | 1.21亿 USD | 1.12亿 USD | 9231.2万 USD |
| 利息收入 | 414.6万 USD | — | — | 187.3万 USD | 2.5万 USD |
| 利息支出 | 8.9万 USD | — | — | — | — |
| 折旧和摊销 | 192.5万 USD | 342.1万 USD | 429.1万 USD | 125.3万 USD | 5万 USD |
| 营业利润 | −1.26亿 USD | −1.37亿 USD | −1.18亿 USD | −1.12亿 USD | −9231.2万 USD |
| 净利润 | −1.24亿 USD | −1.3亿 USD | −1.17亿 USD | −1.1亿 USD | −9228.7万 USD |
公司数据更新于 2026年10月12日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$27.00
上涨空间 277.89%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI688.23万0.00%2.3万亿 USD0.03%US$381.83-0.03%
iShares Russell 2000 ETFIWM310.69万0.00%787.4亿 USD0.19%US$278.67-0.10%
Vanguard Extended Market ETFVXF264.25万0.00%954亿 USD0.05%US$234.43-0.24%
Fidelity Enhanced Small Cap ETFFESM146.74万0.02%64.1亿 USD0.28%US$45.425-0.08%
Vanguard Russell 2000 ETFVTWO118.55万0.01%180亿 USD0.06%US$112.57-0.08%
iShares Micro-Cap ETFIWC37.44万0.03%13.17亿 USD0.60%US$182.41-0.32%
Invesco RAFI US 1500 Small-Mid ETFPRFZ25.89万0.01%26.7亿 USD0.36%US$53.06-0.19%
Vanguard Russell 2000 Value ETFVTWV19.41万0.01%14亿 USD0.06%US$186.37+0.30%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。